Cellanyx Diagnostics is developing a proprietary living cell phenotypic cancer diagnostic platform to aid clinical decision making.Read More >>
Cellanyx is developing a biopsy-on-a-chip technology focused on tumor cell behavior by analyzing multiple phenotypic, biochemical and physical markers of individual living cells cultured from fresh biopsy samples.Read More >>
Cellanyx’s lead test in development is a diagnostic to stratify the risk of local tumor spread and metastasis in men with prostate cancer – low and intermediate risk Gleason grades.Read More >>
Cellanyx is developing a biopsy-on-a-chip technology focused on tumor cell behavior by analyzing multiple phenotypic, biochemical and physical markers of individual living cells cultured from fresh biopsy samples. The company’s suite of biomarkers represent multiple biological pathways and morphological, metabolic and biophysical cellular characteristics such as cell motility and adhesion.The biomarkers are accessible through a method of cell culture and analysis of living tumor cells utilizing a proprietary extracellular matrix and microfluidic chip that mimic the cellular microenvironment, machine vision and learning algorithms. These algorithms distinguish tumor cells from normal cells, and further, generate quantitative, actionable metrics that predict local tumor growth (i.e. oncogenic potential -OP) and distant spread (i.e. metastatic potential – MP).
The Cellanyx living cell biomarker platform has potential use in cancer diagnosis, and prognosis for a wide range of human tumors. The technology has demonstrated the ability to distinguish cancer cells from normal cells in several tissue types. In addition, the technology has additional future application as a research tool for drug development.
Cellanyx’s technology platform is a live-cell-based, biopsy-on-a-chip, technology that assesses patient biopsy samples with single cell resolution to discern and interpret the inherent heterogeneity of cancer with the ability to identify 2 cancer cells with in a population of 100 patient derived cells. By objectively quantifying molecular and phenotypic biomarkers in living biopsy samples, Cellanyx can provide solutions towards 1. diagnostics and prognostics, 2. phenotypic and molecular biomarker discovery, development and validation, and 3. patient stratification with in drug and therapeutic clinical trials.
July 23, 2015:
Recent Press Highlights Cellanyx’s Progress
Boston Business Journal
Wall Street Journal: Daily Startup Blog
Dow Jones Private Equity & Venture Capital News Portal
May 11, 2016:
Cellanyx Demonstrates Clinical Validation of a Novel Live-Cell Phenotypic Biomarker-based Diagnostic Assay for Prostate Cancer.
Abstract: Clinical Validation of a live-cell phenotypic biomarker – based diagnostic assay for the prediction of adverse pathology in Prostate Cancer.
Best Poster Award, 2016 American Urological Association, Prostate Cancer Markers II Moderated Poster Session
Presented at AUA, 2016.